title: Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
abstract: BACKGROUND
  Trabectedin plus pegylated liposomal doxorubicin (PLD) proved efficacious as second-line treatment for patients with recurrent ovarian cancer (ROC).
  
  
  METHODS
  We report a single-center retrospective analysis of the efficacy and tolerance of trabectedin 1.1 mg/m2 every 3 weeks in a cohort of real-life ROC patients.
  
  
  RESULTS
  From February 2012 to January 2014, 17 patients were treated with trabectedin alone or combined with PLD. Median age was 61 years (range: 48-78). Performance status was 0-1 in 16 patients (94%). Disease response rate was 53% and disease control rate was 76%. At the end of the follow-up, 8 patients (47%) were alive. Median overall survival was 17.6 months (95% CI 13.6 to not reached). Median progression-free survival was 6.7 months (95% CI 5.4-10.0). The most frequent grade 3-4 toxicities were neutropenia (n = 4, 24%) and nausea/vomiting (n = 4, 24%).
  
  
  CONCLUSIONS
  Trabectedin combined with PLD seems efficient in and well tolerated by real-life ROC patients.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Moriceau
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.forename: Benoîte
authors.initials: B
authors.lastname: Méry
authors.forename: Alexis
authors.initials: A
authors.lastname: Vallard
authors.forename: Cécile
authors.initials: C
authors.lastname: Pacaut
authors.forename: Jane-Chloé
authors.initials: JC
authors.lastname: Trone
authors.forename: Sophie
authors.initials: S
authors.lastname: Espenel
authors.forename: Claire
authors.initials: C
authors.lastname: Bosacki
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Jacquin
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004149:Dioxoles / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage; D000077606:Trabectedin; D016896:Treatment Outcome
chemical_list: D004149:Dioxoles; D044005:Tetrahydroisoquinolines; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D000077606:Trabectedin